FdaApplication
NDA 050824
Identifiers
- fda_app_no: NDA050824
Properties
| Property | Value |
|---|---|
| applicant_name | CUMBERLAND PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2011-02-08 |
Revenue by product
OMECLAMOX-PAK
| Period | Revenue |
|---|---|
| Q3 2025 | $0.0M* |
| Q2 2025 | $0.0M* |
| Q1 2025 | $0.0M* |
| Q3 2024 | $0.0M* |
| Q2 2024 | $0.0M* |
| Q1 2024 | $0.0M* |
| Q3 2023 | $0.0M* |
| Q3 2022 | $0.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OMECLAMOX-PAK | AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE | 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL |
1 product